Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 
Bristol-Myers Squibb Co at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 03:40PM GMT
Release Date Price:
$63.42
(-2.39%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello. Welcome to Day 2 of the UBS Global Healthcare Conference. My name is Navin Jacob. I'm a senior analyst covering large cap pharmaceuticals and some mid-cap biotech.
Our next presentation of fireside chat is with Bristol-Myers Squibb. It's my pleasure to have with me Chris Boerner, Chief Commercial Officer; as well as Samit Hirawat, Chief Medical Officer.
Thank you, both Chris and Samit, for joining us today.
Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
It's our pleasure.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Perfect. Well, let's -- we can't escape COVID, obviously. So maybe we'll just start off with a few questions there.
Chris, given that Bristol is
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers